Senior Counsels Jason Drori and Simon Elliott contributed an article to IPPro Patents, “The PRICED Act: A Bold Attempt to Change the Biologics Market,” on August 17, 2016. The article examined the Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act proposed legislation that aims to reduce the market exclusivity period for new biologics from 12 to seven years in the United States. Drori and Elliott discussed how the PRICED Act may be a more direct threat to the biologics industry and risks upsetting a delicate balance.
Related Insights
13 December 2024
Events
Korean Startups & Entrepreneurs: Innovation Weekend
Join Foley & Lardner, the host and sponsor, on December 13th for Day 1 of the KSE Innovation Weekend, dedicated to empowering founders and aspiring entrepreneurs.
08 January 2025
Events
Whistleblower Protections: Navigating Health Care Employment & Labor Rights
Events in our recent history — the COVID-19 pandemic, increase in financial incentives for whistleblowers, and expansion of laws providing whistleblower procedures — have resulted in a spike in the number of whistleblower complaints received by regulators and employers globally.
12 December 2024
Blogs
Stellantis and UAW File Dueling Motions to Consolidate String of Lawsuits Regarding Strike Threats on Opposite Coasts
The nationwide fight continues between Chrysler owner Stellantis and the United Auto Workers Union (“UAW”) and its local chapters regarding the UAW’s threats to strike if Stellantis does not move forward with planned investment in its U.S. operations.